Helluva drug(s)! CMS spends ~$8B/yr on Keytruda,Opdivo,Rtxn,Avstn,Hcptn CMS spends ~$1.5B/yr on ALL RADIOTHERAPIES (proton included!) If CMS finagled a 1% discount/yr on these 5 drugs it would save more than RO-APM is projected to per year

The AlphaBet trial Peter Mac Cancer Centre The Lancet Oncology release today ESMO - Eur. Oncology #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future

Speaking at #SABR25 Dr Alison Tree 💙 raises the issue of relative underfunding of #RadOnc research 📢 <5% of cancer research funding is directed towards surgical or radiotherapy related research Yet, radiotherapy is a highly cost effective anti-cancer treatment modality

Randomized Trial Spine SBRT Target Tumor only vs. Tumor+ Elective Coverage ↑↑tumor control with Elective Target coverage academic.oup.com/neuro-oncology…

PDBrown This is fantastic! How do you reconcile elective low dose adjacent compartment vs. to entire vertebral body as per DOSIS? I have been enjoying DOSIS in my practice lately as 20/5 elective to whole VB with homogenous SIB to 40/5 for non-epidural extent cases as it is coherent and

Some great news! Robert Anton Olson ‘s SABR-COMET-3 completed accrual today!! 330 randomized with 1-3 Mets, primary endpoint OS. Biomarker studies led by Alison Allan, PhD and Rohann Correa. Readout maybe in 2027, with COMET10 likely in 2026.

What is the ideal duration of hormone therapy for the treatment of prostate cancer? youtu.be/fezpilkaelM Video summary of jamanetwork.com/journals/jamao…

When it comes to AI auto-contouring, are residents and faculty seeing it the same way? A new study by Alex Qian and Nikhil Kotha, MD shows differences between the two groups. practicalradonc.org/article/S1879-… Residents reported: • Faster CT-based anatomy learning • Major time

We are looking for a locum consultant uro-oncologist for 6 months from March next year. Come and join our friendly team! royalmarsden.nhs.uk/current-vacanc…

This might be the most badass brief report I’ve read in a long time. In NEJM A team just published what feels like a glimpse straight into the future of cellular therapeutics: successful survival and function of transplanted allogeneic, CRISPR-edited beta cells with zero

The STONE Trial is officially active. With over 20 Italian centers involved, the study aims to strengthen the evidence on role of SBRT for unresectable primary renal tumors, a safe and effective ablative treatment #SBRT #radiotherapy #kidney Giulia Marvaso Giulio Francolini

📸 Today’s Board meeting at the ESTRO office! Fruitful strategic discussions, productive exchanges, and a positive, collaborative spirit throughout. 🙏 Thank you everyone for joining and contributing — great to see the team working together to drive ESTRO forward. ✨

🧨 Join us for #PCa #SBRT Symposium by Stefano Arcangeli & Denis Panizza with 🔝tier international faculty Piet Ost Cédric Draulans Constantinos Zamboglou and 🌟Italian RadOncs together with ESTRO President prof. Barbara Jereczek-Fossa 🔗Registrations open—limited seats tinyurl.com/sbrt2026 Valeria Faccenda

The whole medical publishing ecosystem (free content, free peer review, but $$ to publish/read) is a bizarre, exploitative business model. Even if one believes clinicians owe some degree of unpaid "academic service," it’s absurd publishers profit so massively off our free labor.

Conference travel costs add up & discretionary funds are limited. Matt Spraker has generously committed to personally funding four $500 travel awards for trainees & patients. Application process minimal. Seems like a great opportunity.

18F FDG PET CT in Bladder Cancer #GlobalForum25 #BLADDR25 PET CT is quietly becoming one of the most practice changing tools in MIBC. Why it matters: it picks up hidden mets that conventional staging often misses. 🧲 Diagnostic power Sensitivity around 89 percent, specificity

Excellent read: “Epic was never built to ingest or learn from this scale of data. It was built to satisfy billing requirements, regulatory checklists, and documentation workflows. That is the beginning and end of its architecture. It is not a learning system, much less an AI

|GnRH antagonists give faster LUTS relief in prostate cancer #PROSCA25 #GlobalForum25 Urinary symptoms matter in men starting RT plus ADT. Across multiple trials (Anderson, Mason, Axcrona), one signal is crystal clear: 🟦 Degarelix and other antagonists drop IPSS faster than

🔐 One of the key limitation for the implementation of urinary organs-at-risk in treatment planning is the large interobserver variability 🔑 Here we provide a fully available nn-Unet method for automatic segmentation of these small urinary structures! ctro.science/article/S2405-…

Please fell free to use this algorithm within your trials- and for your clinical practice 🙏 Full link to the code within the article!! 🤍 Thanks to the LTSI for their support and their trust for my PhD